Speech and language therapy versus placebo or no intervention for speech problems in Parkinson's disease

Clare P Herd; Claire L Tomlinson; Katherine HO Dean; Marian C Brady; Christina H Smith; Catherine Sackley; Carl E  Clarke

doi:10.1002/14651858.CD002812.pub2

Speech and language therapy versus placebo or no intervention for speech problems in Parkinson's disease

Clare P Herd, Claire L Tomlinson, Katherine HO Dean, Marian C Brady, Christina H Smith , Catherine Sackley, Carl E Clarke

NMAHP

Research output: Contribution to journal › Article

Abstract

Parkinson's disease patients commonly suffer from speech and vocal problems including dysarthric speech, reduced loudness and loss of articulation. These symptoms increase in frequency and intensity with progression of the disease). Speech and language therapy (SLT) aims to improve the intelligibility of speech with behavioural treatment techniques or instrumental aids.

Original language	English
Article number	Art. No.:CD002812
Journal	Cochrane Database of Systematic Reviews
Issue number	8
DOIs	https://doi.org/10.1002/14651858.CD002812.pub2
Publication status	Published - 2012

Keywords

speech therapy
language therapy
placebo
Parkinson's disease

Documents and Links

10.1002/14651858.CD002812.pub2

Fingerprint Dive into the research topics of 'Speech and language therapy versus placebo or no intervention for speech problems in Parkinson's disease'. Together they form a unique fingerprint.

Cite this

Herd, C. P., Tomlinson, C. L., Dean, K. HO., Brady, M. C., Smith , C. H., Sackley, C., & Clarke, C. E. (2012). Speech and language therapy versus placebo or no intervention for speech problems in Parkinson's disease. Cochrane Database of Systematic Reviews, (8), [Art. No.:CD002812]. https://doi.org/10.1002/14651858.CD002812.pub2

@article{58798182c3184cf98ec0d367df664d29,

title = "Speech and language therapy versus placebo or no intervention for speech problems in Parkinson's disease",

abstract = "Parkinson's disease patients commonly suffer from speech and vocal problems including dysarthric speech, reduced loudness and loss of articulation. These symptoms increase in frequency and intensity with progression of the disease). Speech and language therapy (SLT) aims to improve the intelligibility of speech with behavioural treatment techniques or instrumental aids.",

keywords = "speech therapy, language therapy, placebo, Parkinson's disease",

author = "Herd, {Clare P} and Tomlinson, {Claire L} and Dean, {Katherine HO} and Brady, {Marian C} and Smith, {Christina H} and Catherine Sackley and Clarke, {Carl E}",

year = "2012",

doi = "10.1002/14651858.CD002812.pub2",

language = "English",

journal = "Cochrane Database of Systematic Reviews",

issn = "1469-493X",

publisher = "Cochrane Collaboration ",

number = "8",

}

TY - JOUR

T1 - Speech and language therapy versus placebo or no intervention for speech problems in Parkinson's disease

AU - Herd, Clare P

AU - Tomlinson, Claire L

AU - Dean, Katherine HO

AU - Brady, Marian C

AU - Smith , Christina H

AU - Sackley, Catherine

AU - Clarke, Carl E

PY - 2012

Y1 - 2012

N2 - Parkinson's disease patients commonly suffer from speech and vocal problems including dysarthric speech, reduced loudness and loss of articulation. These symptoms increase in frequency and intensity with progression of the disease). Speech and language therapy (SLT) aims to improve the intelligibility of speech with behavioural treatment techniques or instrumental aids.

AB - Parkinson's disease patients commonly suffer from speech and vocal problems including dysarthric speech, reduced loudness and loss of articulation. These symptoms increase in frequency and intensity with progression of the disease). Speech and language therapy (SLT) aims to improve the intelligibility of speech with behavioural treatment techniques or instrumental aids.

KW - speech therapy

KW - language therapy

KW - placebo

KW - Parkinson's disease

U2 - 10.1002/14651858.CD002812.pub2

DO - 10.1002/14651858.CD002812.pub2

M3 - Article

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

SN - 1469-493X

IS - 8

M1 - Art. No.:CD002812

ER -